WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 2 fonti

Draig bags another $65M to speed testing of brain drugs

The cash will support mid-stage trials of a prospect the company claims to have “best-in-disease” potential treating major depressive disorder.

Raccontata dabiopharmadive.commorningstar.com

Confronto fonti

2 prospettive sulla stessa storia
AI · summaries
biopharmadive.comStai leggendo9 g fa

Draig bags another $65M to speed testing of brain drugs

The cash will support mid-stage trials of a prospect the company claims to have “best-in-disease” potential treating major depressive disorder.

originale
morningstar.com9 g fa

Draig Therapeutics Closes Oversubscribed $65 Million Series B to Accelerate Development of Highly Specific…

Draig Therapeutics Closes Oversubscribed $65 Million Series B to Accelerate Development of Highly Specific AMPA and GABAA Receptor Modulators in Neuropsychiatric Disorders

Leggi questa versione → originale

Timeline cronologica

  1. martedì 14 luglio 2026·biopharmadive.com

    Draig bags another $65M to speed testing of brain drugs

    The cash will support mid-stage trials of a prospect the company claims to have “best-in-disease” potential treating major depressive disorder.

  2. martedì 14 luglio 2026·morningstar.com

    Draig Therapeutics Closes Oversubscribed $65 Million Series B to Accelerate Development of Highly Specific AMPA and GABAA Receptor…

    Draig Therapeutics Closes Oversubscribed $65 Million Series B to Accelerate Development of Highly Specific AMPA and GABAA Receptor Modulators in Neuropsychiatric Disorders